Novel synthetic peptide-based vaccine shows promise against prostate cancer

Peptide-based vaccines against cancer are emerging as a promising strategy to target specific tumor antigens and elicit anti-tumor immune responses.1 This type of immunotherapy is an active area of investigation for many solid tumors, including prostate cancer. Currently, prostate cancer represents the second most common malignancy in men worldwide.2 The success of treatments against prostate cancer has been limited due to the emergence of therapy resistance and immune evasion mechanisms, as prostate tumors are immunologically cold.